[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncocytoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncocytoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100443928","renal-cancer-detection-with-liquid-biopsy-100443928",false,"NCT05060783","Renal Cancer Detection With Liquid Biopsy","GaGnostic","Inclusion Criteria:\n\n1. Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.\n2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)\n3. Sign up information consent\n4. Can perform protocol procedure\n\nExclusion Criteria:\n\n1. Non-clear cell Renal cell carcinoma\n2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney\n3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.",[24,25],"Renal Cancer","Oncocytoma","RECRUITING","2024-01-27",{"date":29,"type":30},"2024-01-30","ACTUAL",{"date":32,"type":30},"2021-07-01",{"date":34,"type":20},"2027-07-01",{"name":36,"class":37},"Zealand University Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100499576","biomarkers-of-renal-cancer-100499576","NCT05785052","Biomarkers of Renal Cancer","BRC","Inclusion Criteria for renal-mass patients:\n\n* Men and women over 18 years of age\n* Diagnosis of first episode of renal mass\n* Caucasian race\n* Signed, informed consent\n\nExclusion Criteria renal-mass patients:\n\n* Any other concomitant cancer or history of active cancer in the last 5 years\n* Oncological genetic syndrome\n* Previous history of renal tumour\n* Urothelial cancer\n* End-stage renal disease on hemodialysis\n* Bilateral renal cell carcinoma\n\nInclusion Criteria for control subjects:\n\n* Men and women over 18 years of age\n* Caucasian race\n* Living kidney donor or patient with urological functional diseases (e.g. kidney stones, benign prostate hypertrophy, etc..)\n* Signed, informed consent\n\nExclusion criteria for control subjects:\n\n* History of active cancer in the last 5 years\n* Oncological genetic syndrome\n* End-stage renal disease on hemodialysis or peritoneal dialysis",{"count":47,"type":20},1000,"The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe).\n\nThis new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.",[50,51,25,52],"Renal Cell Carcinoma","Tumor, Solid","Angiomyolipoma",[54,55,50,56,57],"Biomarkers","Urology","Molecular Biomarkers","Oncology","2023-03-14",{"date":60,"type":30},"2023-03-27",{"date":62,"type":30},"2019-06-11",{"date":64,"type":20},"2026-06",{"name":66,"class":67},"Biorek S.R.L.","INDUSTRY",4]